Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P17 vs Humira Pharmacokinetics and Safety Study
NCT03970824Phase 1Completed
- Sponsor
- Celltrion
- Start
- May 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RT-105 in rheumatoid arthritis (RA) and plaque psoriasis (3 arms), sponsored by Celltrion. Primary endpoints: Area Under the Concentration-time Curve From Time Zero to Infinity, Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration and 1 more. Started May 2019; status: completed.
02
Drugs
RT-105
03
Conditions
rheumatoid arthritis (RA)plaque psoriasis
Beyond the preview
Go deeper on NCT03970824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03970824.